摘要
目的探讨乳腺癌组织中CD95、CD44V6的表达与腋窝淋巴结转移的关系及其临床病理意义。方法筛选101例乳腺癌根治标本，癌组织免疫组织化学标记CD95与CD44V6其中40例腋窝淋巴结阴性者淋巴结全部标记MCKo并进行统计学分析。结果在常规病理诊断淋巴结未转移的病例中，免疫组化标记检出9例（22．5％，9／40）有微小转移。CD95与CD44V6的表达在转移组与微转移组相似。淋巴结转移组CD95的阳性率与未转移组之间差异具有统计学意义。当肿瘤〉2cm时，CD95的阳性率及CD44V6的高表达率具有统计学意义（P〈0．05）。结论通过检测乳腺癌组织中CD95与CD44V6的表达，有助于预测淋巴结微小转移情况，为临床判断预后和选择治疗方案提供更加可靠的依据。
Objective To investigate the relationship and clinicopathologic significance between the expression of CD95, CD44V6 and metastasis of axillary lymph node in breast cancer. Methods Immunohistochemistry was used to detect the expression of CD95 and CD44V6 in 101 cases of breast cancer, in which, 40 cases without metastasis in axillary lymph node were detected MCK expression by IHC. The results were analyzed statistically. Results 9 cases of breast cancer with lymph node micrometastasis were observed by IHC in 40 cases without metastasis in axillary lymph node by microscope. The expression of CD95, CD44V6 in lymph node metastasis group was similar as in lymph node micrometastasis group. There was significant difference of CD95 expression between those with lymph node metastasis and those without. The positive rate of CD95 and the high expression of CD44V6 in the cases that the tumor size was over 2 cm were significantly higher than in the cases that the tumor size was less than 2 cm （P 〈0.05）. Conclusion Detection of the expression of CD95, CD44V6 in breast cancer may be helpful to predict the lymph node micrometastasis and provide more dependable evidence for judging prognosis and selecting treatment prescription clinically.
出处
《肿瘤研究与临床》
CAS
2009年第4期248-250,共3页
Cancer Research and Clinic
基金
基金项目：山西省卫生厅科技项目（200411）
